Effect of peroxisome proliferator-activated receptor γ ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction

International Journal of Cardiology

Volumn 113, Issue 1, 2006, Pages 86-91

  Geng, Deng feng ^a   Wu, Wei ^a   Jin, Dong mei ^a   Wang, Jing feng ^a   Wu, Yi mei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Myocardial infarction; PPAR ; Renin angiotensin system; Thiazolidinediones; Ventricular remodeling

Indexed keywords

ALDOSTERONE; ANGIOTENSIN I; ANGIOTENSIN II; COLLAGEN; GLUCOSE; INSULIN; MESSENGER RNA; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; BODY MASS; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HEART HEMODYNAMICS; HEART INFARCTION; HEART VENTRICLE REMODELING; INSULIN BLOOD LEVEL; LEFT CORONARY ARTERY; LIVER; LUNG; MALE; MORPHOMETRICS; MORTALITY; NONHUMAN; ORGAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; SURVIVAL;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; COLLAGEN; INSULIN; LIGANDS; LIVER; LUNG; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; ORGAN SIZE; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; VENTRICULAR REMODELING;

EID: 33750485826     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.03.060     Document Type: Article

References (30)

1. Ito H., Nakano A., Kinoshita M., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 83 (2003) 1715-1721
2. Yue T.L., Chen J., Bao W., et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104 (2001) 2588-2594
3. Yuan Z.Y., Liu Y., Liu Y., et al. Peroxisome proliferation-activated receptor-γ ligands ameliorate experimental autoimmune myocarditis. Cardiovasc Res 59 (2003) 685-694
4. Sakai S., Miyauchi T., Irukayama-Tomobe Y., et al. Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci (Lond) 103 (2002) 16S-20S
5. Nian M., Lee P., Khaper N., et al. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94 (2004) 1543-1553
6. Shiomi T., Tsutsui H., Hayashidani S., et al. Pioglitazone, a peroxisome proliferator-activated receptor γ ligand, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
7. Frantz S., Hu K., Widder J., et al. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 141 (2004) 9-14
8. Lygate C.A., Hulbert K., Monfared M., et al. The PPARgamma-ligand rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 58 (2003) 632-637
9. Geng D.F., Wu W., Jin D.M., et al. Effects of peroxisome proliferator-activated receptor γ activator rosiglitazone on myocardial ischemic-reperfusion injury in rats. Chin J Pathophysiol (Chin) 21 (2005) 872-875
10. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
11. Inzucchi S.E., Masoudi F.A., Wang Y., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28 (2005) 1680-1689
12. Shimoyama M., Ogino K., Tanaka Y., et al. Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 48 (1999) 609-615
13. Furuse Y., Ogino K., Shimoyama M., et al. Ca(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazone. Br J Pharmacol 133 (2001) 1307-1313
14. Hirayama H., Sugano M., Abe N., et al. Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. Int J Cardiol 77 (2001) 75-79
15. Horio T., Suzuki M., Suzuki K., et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 18 (2005) 949-957
16. Ogino K., Furuse Y., Uchida K., et al. Troglitazone improves cardiac function in patients with congestive heart failure. Cardiovasc Drugs Ther 16 (2002) 215-220
17. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003) 2941-2948
18. Masoudi F.A., Inzucchi S.E., Wang Y., et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111 (2005) 583-590
19. Chen K., Li D., Zhang X., et al. Anoxia-reoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPAR-gamma ligand pioglitazone. J Cardiovasc Pharmacol 44 (2004) 682-687
20. Iglarz M., Touyz R.M., Viel E.C., et al. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 42 (2003) 737-743
21. Chen K., Chen J., Li D., et al. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 44 (2004) 655-661
22. Asakawa M., Takano H., Nagai T., et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105 (2002) 1240-1246
23. Yamamoto K., Ohki R., Lee R.H., et al. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104 (2001) 1670-1675
24. Benkirane K., Amiri F., Diep Q.N., et al. PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290 (2006) H390-H397
25. Fukuda N., Hu W.Y., Teng J., et al. Troglitazone inhibits growth and improves insulin signaling by suppression of angiotensin II action in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 163 (2002) 229-239
26. Hattori Y., Akimoto K., and Kasai K. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem Biophys Res Commun 273 (2000) 1144-1149
27. Goetze S., Xi X.P., Graf K., et al. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 452 (1999) 277-282
28. Sugawara A., Takeuchi K., Uruno A., et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142 (2001) 3125-3134
29. Takeda K., Ichiki T., Tokunou T., et al. Peroxisome proliferator-activated receptor gamma ligands downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102 (2000) 1834-1839
30. Diep Q.N., El Mabrouk M., Cohn J.S., et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator activated receptor-gamma. Circulation 105 (2002) 2296-2302